Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a precise nerve block stop shingles pain before it becomes chronic?

NCT ID NCT07732556

Symptom relief Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial compares two ultrasound-guided nerve blocks — the midpoint transverse process to pleura (MTP) block and the erector spinae plane (ESP) block — for treating acute pain from shingles (herpes zoster) on the chest. About 90 adults with moderate to severe pain will receive one of the two blocks, which combine a numbing medication (bupivacaine) with an anti-inflammatory steroid (methylprednisolone). The goal is to see which block provides better pain relief and whether it can prevent postherpetic neuralgia, a chronic pain condition that can linger after the rash heals.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a nerve block using bupivacaine and methylprednisolone
What this could lead to
If one block proves superior, it could offer a more effective way to control shingles pain and reduce the risk of lasting nerve pain.
What could go wrong
This is a small, early-stage comparison. Results may not apply to all patients, and nerve blocks carry risks like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 90 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 21-60 years. * Both sexes. * American Society of Anesthesiologists (ASA) physical status I-II. * Acute thoracic herpes zoster within 30 days of rash onset. * Moderate to severe pain \[numeric rating scale (NRS)≥4\]. Exclusion Criteria: * Refusal to participate. * Coagulopathy or anticoagulant therapy. * Infection at puncture site. * Allergy to study drugs. * Severe psychiatric illness or inability to assess pain. * Previous thoracic surgery deformity. * Uncontrolled Diabetic patient. * Chronic diseases as renal, hepatic, malignancy. * Patients with chronic disease need analgesia. * Patients are coming for more than 3 months (after healing of rash).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute herpes zoster are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

herpes zoster Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute herpes zoster Erector spinae plane block Midpoint transverse process to pleura block Pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tanta University

    RECRUITING

    Tanta, El-Gharbia, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.